5-year overall survival (OS) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with xevinapant plus chemoradiotherapy (CRT) vs placebo plus CRT in a randomized, phase II study

被引：9

作者：

Bourhis, J. ^{[1
]}

Le Tourneau, C. ^{[2
]}

Calderon, B. ^{[3
]}

Martin, L. ^{[4
]}

Sire, C. ^{[5
]}

Pointreau, Y. ^{[6
]}

Ramee, J-F. ^{[7
]}

Coutte, A. ^{[8
]}

Boisselier, P. ^{[9
]}

Kaminsky-Forrett, M-C. ^{[10
]}

Delord, J-P. ^{[11
]}

Clatot, F. ^{[12
]}

Sun, X. ^{[13
,14
]}

Villa, J. ^{[15
]}

Magne, N. ^{[16
]}

Elicin, O. ^{[17
]}

Damstrup, L. ^{[18
]}

Gollmer, K. ^{[19
]}

Crompton, P. ^{[20
]}

Tao, Y. ^{[21
]}

机构：

[1] CHU Vaudois, Dept Radiat Oncol, Lausanne, Switzerland

[2] Inst Curie, Dept Drug Dev & Innovat, Paris, France

[3] Avignon Provence Canc Inst, Oncol Radiotherapy, Avignon, France

[4] William Conqueror Ctr, Radiotherapie, Le Havre, France

[5] South Brittany Hosp Grp, Hop Scorff, Radiotherapie, Lorient, France

[6] Ctr Jean Bernard, Inst Inter Reg Cancerol, Oncol, Radiotherapy, Le Mans, France

[7] CHD Vendee, Onco Hematol Dept, La Roche sur Yon, France

[8] CHU Amiens Picardie, Oncol Radiotherapy Dept, Amiens, France

[9] Montpellier Canc Inst, Oncol Radiotherapie, Montpellier, France

[10] Canc Inst Lorraine Alexis Vautrin, Oncol Med, Nancy, France

[11] IUCT Oncopole, Med Oncol Dept, Inst Claudius Regaud, Toulouse, France

[12] Ctr Henri Becquerel, Serv Oncol Med, Rouen, France

[13] Nord Franche Comte Montbeliard, Dept Radiat Oncol, Montbeliard, France

[14] CHRU Besancon, Dept Radiat Oncol, Montbeliard, France

[15] CHU Grenoble, Pole Cancerol, Dept Radiat, Grenoble, France

[16] Inst Cancerol Lucien Neuwirth, Radiotherapie, St Etienne, France

[17] Univ Bern, Univ Hosp Bern, Inselspital, Dept Radiat Oncol, Bern, Switzerland

[18] Debiopharm Int SA, Clin Res Dept, Lausanne, Switzerland

[19] Debiopharm Int SA, Clin Dev, Lausanne, Switzerland

[20] Debiopharm Int SA, Lausanne, Switzerland

[21] Inst Gustave Roussy, Dept Radiat Oncol, Villejuif, France

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.08.030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA33

引用

页码：S1400 / S1400

页数：1

共 50 条

[31] Docetaxel, ifosfamide and cisplatin (DIP) as induction chemotherapy (IC) followed by chemoradiation (CRT) in patients with locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN)
Specenier, Pol M.
Rasschaert, Marika
Van den Brande, Jan
Huizing, Manon
Dyck, Joke
Altintas, Sevilay
Van den Weyngaert, Danielle
Van Laer, Carl
Vermorken, Jan B.
ANNALS OF ONCOLOGY, 2006, 17 : 181 - 181
[32] Phase I study of gefitinib plus celecoxib in patients with metastatic and/or locally recurrent squamous cell carcinoma of the head and neck (SCCHN).
Wirth, LJ
Haddad, RI
Wieczorek, TJ
Faucher, JL
Clark, JR
Norris, CM
Posner, MR
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 498S - 498S
[33] Phase II study of synchronous chemoradiotherapy with capecitabine in patients with locally advanced squamous cell carcinoma of the head and neck
Jegannathen, A.
Mais, K.
Sykes, A.
Lee, L.
Yap, B.
Birzgalis, A.
Homer, J.
Ryder, D.
Slevin, N.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[34] PANITUMUMAB (PMAB) ADMINISTERED WITH CHEMORADIOTHERAPY (CRT) FOLLOWING INDUCTION CHEMOTHERAPY (IC) IN THE TREATMENT OF PATIENTS (PTS) WITH LOCO-REGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
Tabernero, J.
Hitt, R.
Cervantes, A.
Rolland, F.
Valverde, C.
Lalami, Y.
Baselga, J.
Shepherd, S.
Gansert, J.
Vermorken, J.
ANNALS OF ONCOLOGY, 2008, 19 : 218 - 218
[35] A phase 2 randomized trial of radiotherapy (RT) plus panitumumab compared to chemoradiotherapy in patients with unresected, locally advanced squamous cell carcinoma of the head and neck (SCCHN): interim pooled safety analysis
Giralt, J.
Trigo, J. M.
Nuyts, S.
Ozsahin, M.
Markowitz, A. B.
Daisne, J.
Skladowski, K.
Lonchay, C.
Holeckova, P.
Smitt, M.
EJC SUPPLEMENTS, 2009, 7 (02): : 475 - 475
[36] SINGLE-CENTRE EXPERIENCE OF QUALITY ASSURANCE (QA) MEASURES IN A PHASE 2 TRIAL OF RADIOTHERAPY (RT) plus PANITUMUMAB VS CHEMO-RT (CRT) IN PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
Khan, S.
Fujak, E.
Meyer, F.
Ceccarelli, P.
Naehrig, D.
Terwey, J.
Meister, A.
ANNALS OF ONCOLOGY, 2010, 21 : 319 - 320
[37] Randomized phase II trial of cisplatin and radiotherapy with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Martins, Renato
Parvathaneni, Upendra
Sharma, Anand K.
Raez, Luis E.
Papagikos, Michael A.
Yunus, Furhan
Bauman, Julie E.
Eaton, Keith D.
Liao, Jay Justin
Mendez, Eduardo
Futran, Neal
Kurland, Brenda F.
Wang, David X.
Xiaoyu, Shawn
Wallace, Sarah G.
Hayes, David N.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[38] HEALTHCARE RESOURCE UTILIZATION (HRU) SURVEY TO INFORM HRU DATA COLLECTION ALONGSIDE THE DOUBLE-BLINDED TRILYNX STUDY EVALUATING XEVINAPANT IN COMBINATION WITH CHEMORADIOTHERAPY VERSUS PLACEBO PLUS CHEMORADIOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY-ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (LA SCCHN)
Gandola, A.
Orfanos, P.
Sarkouh, Ait R.
Bobiak, S.
Stanton, C.
Vossen, C.
De Cock, E.
VALUE IN HEALTH, 2022, 25 (01) : S272 - S272
[39] Phase II Study of Cetuximab Plus Concomitant Boost Radiotherapy in Japanese Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Okano, Susumu
Yoshino, Takayuki
Fujii, Masato
Onozawa, Yusuke
Kodaira, Takeshi
Fujii, Hirofumi
Akimoto, Tetsuo
Ishikura, Satoshi
Oguchi, Masahiko
Zenda, Sadamoto
de Blas, Barbara
Tahara, Makoto
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (05) : 476 - 482
[40] Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck
Kim, JG
Sohn, SK
Kim, DH
Baek, JH
Jeon, SB
Chae, YS
Lee, KB
Park, JS
Sohn, JH
Kim, JC
Park, IK
BRITISH JOURNAL OF CANCER, 2005, 93 (10) : 1117 - 1121

← 1 2 3 4 5 →